Member Info for M216

Bought another 9k shares this morning, I keep thinking this’ll be the last tranch, but as long as the chance to but at or below my average I’ll keep buying. Looking forward to a life changing 2026/7, good luck all investors

Good raise, no issues with obtaining financial support from investors. I wonder why this could be an issue for anyone investing in Avacta, unless you were after a quick profit. I would expect the SP to trend upwards until the next RNS, but still leaves time for those of us who value the prospects of the company to buy more shares. Good news all round imo.

Took and his snivelling sidekick are a pair of egocentric fools. Wouldn’t put any faith in the conspiracy that they’re paid derampers, wouldn’t think either would last in any organisation.

I have finally (after six years) finished buying. Small drinks and drabs from 7,775 shares to nearly 70k.

Cannot believe there is a better potentially life-changing company to be invested in, and happy, relaxed and supremely confident that at the least this will finance a comfortable early retirement, and more likely that and help the kids out with a house deposit and many great adventures. Good luck all, and hope Touk and WYN don’t run out of crayons to chew while we wait.

HL is back online

100:1 might not mean very much must be one of the most vacuous statements i’ve read on here. i hope you were s********* to yourself when you typed that. you’re clearly are a bit of an ass, and a reminder to login every day.

There is something to that - some AVCT posters on X are unnecessarily rude and entitled. It doesn't help the rest of us, but can't blame someone for getting on with the job and not engaging so much in social media.

I think the idea of researching a stock is to look at (in this case), is the science supporting the business case for the business, not someone's view of where this may take the SP. That is down to a personal view, and we all have our own view of where the SP will end up, either if Avacta end up as a commercially viable business or are taken over before that happens.

You are exactly the sort of poster who newbies should be ignoring. Give investors some credit for being able to evaluate their own choices, they do not need hysterical posters like you to inform their decisions.

Reported for the personal attacks. Apologies if you are twelve, because that at least would explain the tantrum.

Fantastic to have confirmation, thank you for sharing. This for me is confirmation that funding is sorted, and AVCT are awaiting a good time to announce to the market (could be a number of good reasons for this). Wyn and the gang , be careful and don't choke on your crayons this afternoon.

If the DX business is now profitable, which we were told it was in Q3, then the price paid will depend on what the buyer(s) are willing to pay. £20m is now at the low end of expectations, which is a positive development.

Brexit may have had a 'small' part to play, and still is.

£12-£25 and I think that will be a good investment.

Another payday and the SP is too good to miss again, and has been since the Jan-23 RNS, when it was confirmed the drug was releasing in the TME. For me it's been a test of patience, and the filter on here has been a blessing - (you know the ones) for my peace of mind. Been in since Feb-20, thinking 6-12 months investment, and have just kept accumulating until the inevitable takeover. I think by Q2-Q3 next year we're done, probably pre dual listing.

PL/Timster/ Bella, and some others, thank you for keeping this forum balanced, (and in Bella's case intelligent), and Wyn, good luck in the care home when they do wheel you away.

I’d be interested to hear what the thoughts are about Annovis Bio. Stage four trials re; Parkinson’s Disease. US company.

Rambo: "This is why our own constructive comments vanish".

Who are you referring to in the collective? Who are you working with and why?

Printerman62, another pointless poster for the bin

YTeeBack - why are you wasting your time posting. You clearly have nothing constructive to say about anything, hence your negative/libellous posting history. Reported and filtered.

Foreverwaiting. To be fair to AS (and I agree we need to hear more about the fund raises), he has done a remarkable job, with the company he has been pivotal in building, and the success of the trials to date. We will probably all (except for a few non-entities on here) be lauding him before the year is out. He should be rightly proud of his achievements, and calling people like him names is a bit pathetic, whatever our concerns.

Energy - 'Has any company ever presented chemo results to the FDA with so little side effects',

I think probably not - thank you for the level-headed positivity. It's easy to become swamped with the trolls' BS, and underestimate the probability of the amazing success story we have here.

JV: my read is that the data presented so far supports optimal dosing lower for longer, so they are not expecting the 2 week trial to go beyond C4.

My opinion, there's a time for investments, and that would have been after any licensing deals, when you have clearer routes to cash generation. The profits Launch make may cover the interest and other associated deal/integration costs over time, but was a terrible deal for shareholders.

AVCT - have re-read the RNS's at the time of the Height's raise, and the MM notes at the time.

On reflection, MM was positive about the DX acquisition, not sure where you get your reason for talking about someone's margin call - that is making a negative assumption, and you're playing the man not the ball, unnecessary. The reason for our travails have not been all AS or Avacta's fault. From a business/ science perspective they have been remarkably successful, and who here would think that a company having a trial demonstrating early signs of efficacy and amazing safety profile, would not have this somehow reflected in their SP, and not have BP biting their hands off for a valuable license deal. The above was the case in Jan 23 RNS.

To their credit they didn't take the cheap license deals that were 'offered', thereby devaluing the trial and the product. I would still, however like to hear some reasoning for the pump fake given to shareholders, around "funding, don't worry about it" followed months later, without retraction of the above statement, by a 50p fundraise to regain confidence that AS does have some alignment with shareholders, and we are not going to be trodden underfoot for AS's ambitions for Avacta and himself. I've been invested since Feb-21, and have been happy buying more shares each month for the past two years. This month, I would like to hear AS talking to shareholders openly.